Leadership Team

Our leadership team is comprised of experienced, diverse individuals bringing together a collective expertise in gene therapy, rare diseases, and neurology.

Topher Brooke

Chief Operating Officer

Christopher ‘Topher’ M. Brooke has nearly two decades of healthcare industry experience, a passion for science and patients, and a strong track record of delivering results and developing teams.

Karen Kozarsky, PhD

Chief Scientific Officer

Karen Kozarsky has 25+ years of experience in gene therapy, with a primary focus on the development of gene therapy for inherited rare diseases utilizing adeno-associated virus vectors...

David M. Weiner, MD

Chief Medical Officer

Dave Weiner has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological and rare diseases.

Michael Alexander, JD, PhD

General Counsel, Head of IP

Michael Alexander has 27+ years of experience in the pharmaceutical industry providing legal guidance and strategic business advice in support of global research and development...

Carolyn Carroll

Chief People Officer

Carolyn M. Carroll brings to SwanBio more than 20 years of experience in organizational leadership and cultural development as well as human resources expertise in healthcare...

Janet Ogden, PhD

Head of Portfolio Development

Janet Ogden brings more than 25 years of combined experience in drug discovery, translational research & medicine, clinical development, and integrated global program leadership...

Topher Brooke

Chief Operating Officer

Christopher ‘Topher’ M. Brooke has nearly two decades of healthcare industry experience, a passion for science and patients, and a strong track record of delivering results and developing teams.

Karen Kozarsky, PhD

Chief Scientific Officer

Karen Kozarsky has 25+ years of experience in gene therapy, with a primary focus on the development of therapies for inherited rare diseases, utilizing adeno-associated virus (AAV) vectors.

Our Swans are united in our drive to advance gene therapy and make a meaningful impact for patients who can’t wait.

David M. Weiner, MD

Chief Medical Officer

Dave Weiner has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological and rare diseases.

Michael Alexander, JD, PhD

General Counsel, Head of IP

Michael Alexander has 27+ years of experience in the pharmaceutical industry providing legal guidance and strategic business advice in support of global research and development...

Each Swan brings our own personal commitments to address neurological conditions – all together this creates an authentic, shared passion and sense of urgency to our team.

Carolyn Carroll

Chief People Officer

Carolyn M. Carroll brings to SwanBio more than 20 years of experience in organizational leadership and cultural development as well as human resources expertise in healthcare...

At Swan, there is passion, humility, and authenticity in what we say and what we do. The focus is on our patients.

Janet Ogden, PhD

Head of Portfolio Development

Janet Ogden brings more than 25 years of combined experience in drug discovery, translational research & medicine, clinical development, and integrated global program leadership...

At SwanBio, we collaborate to make an impact, putting cross-functional teams at the center of our organization.